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Background. Contrast enhanced ultrasound (CEUS) is a dynamic and continuous modality providing real-time view of
vascularization and flow distribution patterns of different organs and tumors. Nevertheless its intraoperative use for brain tumors
visualization has been performed few times, and a thorough characterization of cerebral glioma had never been performed before.
Aim. To perform the first characterization of cerebral glioma using CEUS and to possibly achieve an intraoperative differentiation
of different gliomas. Methods. We performed CEUS in an off-label setting in 69 patients undergoing surgery for cerebral glioma.
An intraoperative qualitative analysis was performed comparing iCEUS with B-mode imaging. A postprocedural semiquantitative
analysis was then performed for each case, according to EFSUMB criteria. Results were related to histopathology. Results. We
observed different CE patterns: LGG show a mild, dotted CE with diffuse appearance and slower, delayed arterial and venous
phase. HGG have a high CE with a more nodular, nonhomogeneous appearance and fast perfusion patterns. Conclusion. Our study
characterizes for the first time human brain glioma with CEUS, providing further insight regarding these tumors’ biology. CEUS
is a fast, safe, dynamic, real-time, and economic tool that might be helpful during surgery in differentiating malignant and benign
gliomas and refining surgical strategy.
1. Background
Cerebral gliomas, both HGG and LGG, are a daunting chal-
lenge. Complete tumor resection remains the best treatment
option as long as it can be achieved without neurological
sequelae.The role of imaging techniques in surgical resection
of brain lesions is crucial in every step of surgery: they
help planning surgical strategy, provide orientation during
surgery, and indicate tumor boundaries and relationships
with eloquent areas and vital structures, thus enhancing
precision, accuracy, and safety for the patients while max-
imizing resection [1–4]. In recent years we are witnessing
an increased use of ultrasounds (US) in neurosurgery, as their
reliability as an intraoperative tool for tumor detection has
been shown in multiple studies [5–9]. US obviates the need
for high costs and specialized surgical instruments. However,
although standard US B-mode imaging is excellent for tumor
localization, little information is provided regarding micro-
circulation and perfusion dynamics, even when integrated
with Doppler sonography [10–13].
The use of contrast agents in medical imaging is aimed at
enhancing differences and characteristics of various organs,
vessels, and cavities, making their visualization more sim-
ple and efficient, and US are routinely used in diagnostic
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radiology. Contrast enhanced ultrasound (CEUS) is nowa-
days an established technique for many organs, as it allows,
among other things, better detecting neoplastic lesions [14].
Furthermore, for their ability to highlight microcirculation,
contrast agents are used in oncology in order to quantify
the flow characteristics through an organ or tumor which
differ according to the type of lesion and the organ involved
[15–19]. The main clinically recognized application is the
characterization of focal liver lesions [20]: CEUS with low-
transmit power insonation allows real-time assessment of
contrast enhancement and vascularity of focal lesions during
the different dynamic phases, after injection of an intravenous
contrast agent. Contrast agents containingmicrobubbles have
been found to give the highest contrast with ultrasound
scanning [21, 22].Themicrobubbles consist of air or inert gas
encapsulated in a layer of protein or polymers. Microbubbles
are typically 5 micrometers in diameter, a similar size to
red blood cells, and can therefore be transported into the
smallest capillaries and across the lungs, thus allowing the
visualization of the arterial system after venous injection.The
pharmacokinetics of the microbubbles is quite different from
that of contrast agents used for CT and MRI which generally
diffuse in the interstitial space [15, 16, 23]. Second generation
US contrast agents are clinically safe and well tolerated [24].
Given these technical features, it seems worthwhile and a
promising effort to test this method for brain gliomas char-
acterization and for its role in maximizing surgical resection,
as already carried out by the radiological community for
other organs. In fact, CEUS could provide us with further
insight into glioma biology: being a dynamic and continuous
modality it offers a real-time direct view of the degree of
vascularization, microcirculation, flow distribution patterns,
and tissue resistances of the different type of gliomas, adding
all these pieces of information to the anatomical ones
obtained with standard B-mode imaging.
Nonetheless its use in cerebral surgery has only been
attempted few times so far [25–27], and there are no guide-
lines provided on this regard.
In this paper the authors describe, for the first time, the
different patterns of cerebral gliomas enhancement using the
CEUS technique, as compared with the lesion characteriza-
tion achieved by using preliminary baseline US.
2. Material and Methods
2.1. Study Design and Patient Population. We performed
intraoperative CEUS in an off-label setting in patients with
supratentorial cerebral gliomas (both HGG and LGG) con-
firmed on preoperative MRI, undergoing craniotomy for
tumor removal.
We included patients with no cardiopathy (New York
Heart Association, NYHA I-II) and a good general status
(ASA I-III).
All patients underwent preoperative assessment con-
sisting of a thorough neurological and general conditions
evaluation.
All patients were fully informed regarding their treatment
and procedure and a written informed consent was obtained.
The principles of the Declaration of Helsinki and the Euro-
pean Federation of Societies for Ultrasound in Medicine and
Biology (EFSUMB) recommendations on CEUS [18, 28] had
been followed.
2.2. Equipment andContrast Agent. Weused a last generation
ultrasound device (MyLab, Esaote, Italy) with a 3–11MHz
linear probe.
The US system is equipped with Virtual Navigator
software (MedCom, Germany) that permits fusion imag-
ing between preoperative MRI and real-time intraoperative
ultrasound imaging, allowing for neuronavigation.
As a contrast agent we used sulphur-hexafluoride,
a second-generation ultrasound contrast agent (SonoVue,
Bracco, Italy).
CEUS scanning is performed using contrast-tuned imag-
ing (CnTI) technology that allows for real-time angiosonog-
raphy, using second generation ultrasound contrast agents.
Contrast-tuned imaging permits a selective synchronization
of the US system to the signal produced by the microbubbles
after transmission of a single-frequency pulse at the sulfur
hexafluoride resonance frequency. The standard US imaging
had been improved by CPI (combined pulsed imaging), a
sophisticated algorithm based on a mix of high and low fre-
quencies that improves B-mode penetration and resolution.
2.3. Procedure and Data Analysis. Weperform a preoperative
MRI based surgical planning. The craniotomy is performed
with neuronavigation using standard preoperative MRI and
coupled US using Virtual Navigator (Esaote, Italy).
The ultrasound apparatus is brought in and the 3–11MHz
intraoperative linear US probe (LA 332, Esaote, Italy) is
placed in a transparent plastic surgical sterile sheath (Civco,
USA), provided with US specific transducing gel.
After bone flap removal the US navigated probe is placed
on the dura mater for scanning and standard B-mode imag-
ing is acquired. All lesions are initially evaluatedwith B-mode
imaging: they are defined as highly, mildly hyper-, iso-, and
hypoechoic compared to normal brain parenchyma. Other
lesion characteristics taken into account are diffuse or cir-
cumscribed appearance, homogeneous versus heterogeneous
lesions, and presence of cystic/necrotic areas. The lesion is
then identified on the two axes and measured. The lesion
is also localized with neuronavigation on the corresponding
coupled MRI.
Intraoperative CEUS is performed with the linear probe
using low-power insonation and the obtained harmonic
signals transduced with CnTI algorithm that allows for real-
time and continuous imaging. Before microbubble contrast
agent injection the focus is positioned below the level of the
lesion.The contrast agent (SonoVue, Bracco, Italy) is injected
intravenously by the anesthesiologist, as a bolus of 2.4mL
(5mg/mL), followed by a flush of 10 cc. saline. The timer
is started after UCA injection and perfusion dynamics is
described starting from UCA arrival in major vessels; digital
cine clips are registered continuously during baseline US
scanning and during the different vascular phases.
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Table 1: Summarizing CEUS features of different grades of human cerebral gliomas.
Brain Lesion Number of pts. Echogenicity Appearance Cystic areas and/ornecrosis
Arterial
phase
CEUS
peak
Venous
phase CE
Low-grade glioma 22 Iso/hyperechoic Diffuse; homogeneous Small/microcysts 15󸀠󸀠 20󸀠󸀠 30󸀠󸀠 Mild
Anaplastic glioma 11 Iso/hyperechoic Diffuse; homogeneous Small/microcysts 10󸀠󸀠 15󸀠󸀠 20–25󸀠󸀠 Mild/high
Glioblastoma 36 Hyperechoic Diffuse/circumscribed;heterogeneous
Large necrotic
areas 2-3
󸀠󸀠 5󸀠󸀠 10󸀠󸀠 High
After UCA injection, a first intraoperative qualitative
analysis was performed, aimed at determining whether a
contrast enhancement was detectable for every lesion and at
its afferent and efferent vessels visualization. Data were also
stored in the US device for offline analysis.
An offline data analysis of the CEUS cine clips was
performedusing a semiquantitative assessment, following the
EFSUMB guidelines. Gliomas patterns of contrast enhance-
ment (CE) were evaluated following the EFSUMB guide-
lines: timing (arterial and venous phase (time is given as
range)), degree of CE (low, mild, and high; comparison
with brain parenchyma), and contrast distribution (cen-
tripetal/centrifugal pattern, visibility of afferent/efferent ves-
sels, intralesional vessels, and cystic/necrotic areas).
All data obtained by online and offline analysis were
correlated with histopathology.
3. Results
Our population consisted of 69 patients (mean age 49 years;
age range 12–71 years) who underwent surgery for supra-
tentorial cerebral glioma. Histopathological data showed 47
HGG and 22 LGG. We further divided the two groups
in two other subgroups: HGG group was composed of 36
glioblastomas (GBM) and 11 anaplastic astrocytomas (ANA).
LGG group had 18 astrocytomas (ASTRO) and 4 oligoden-
drogliomas (OLIGO). Ultrasound findings were correlated
with histopathology.
On standard US B-mode imaging glioblastoma (𝑛 − 47)
appeared all hyperechoic compared to brain parenchyma,
with a heterogeneous appearance composed of multiple
well-defined nodular areas and others with diffuse mar-
gins. Size ranged from 3 to 7 cm of maximal diameter.
All but three lesions had cystic/necrotic areas. Anaplastic
astrocytoma (𝑛 − 11) ranged from 4 to 7 cm in diame-
ter. All three appeared hyperechoic with a diffuse, dense
texture, with some areas more hyperechoic compared to
the rest of the lesion. No cystic/necrotic areas were noted.
The brain/tumor interface was not everywhere clearly
visible.
In the LGG group all lesions (𝑛 − 22) appeared mildly
hyperechoic compared to brain parenchyma. Size ranged
from 3 to 9 cm in maximum diameter. All lesions had a
homogenous texture with blurredmargins at the brain/tumor
interface except one oligoastrocytoma which had a discrete
appearance with clear border. Microcysts were visible in 5
cases only.
After ultrasound contrast agent (UCA) injection different
patterns were observed (Figures 1 and 2). All data are
summarized in Table 1.
In the HGG group we further divided CE pattern into the
two histological subgroups.
GBMs (𝑛 − 47) have rapid arterial and venous phase
with a very fast arterial phase (2-3 seconds), chaotic transit
of microbubbles within the lesion, and a CE peak at 5
seconds. CEUS transit time is very fast with a venous
phase at 10 seconds. The major arterial supply was clearly
visible, as well as the venous drainage system, almost invari-
ably towards the periventricular zone. GBMs appear all
hyperenhanced compared to normal brain parenchyma and
have a very strong and intense contrast enhancement with
a persistent parenchymal phase. They have an irregular and
heterogeneous CE pattern with an alternation of nodular
high contrast dense pattern with ring-like enhancement
surrounding hypoperfused necrotic or nonperfused cystic
areas. Many intralesional vessels are noted. We did not
observe hypoperfused areas in only 6 cases, while 5 other
cases only had small scattered hypoperfused areas. Tumor
borders are better defined after CE than in standard B-mode
imaging. GBMs showed a rapid refilling (around 3-4 seconds)
after rapid sonication at high mechanical index sonication.
ANAs appeared to have a slower arterial phase compared
to GBMs (10 sec), with a CE peak at around 15 seconds after
UCA arrival. The transit of the microbubbles is slower and
less chaotic and the venous phase is delayed as well (20–25
seconds), determining a lesion transit time of 5–10 seconds.
Arterial supply and venous drainage are less identifiable than
in GBMs. ANAs appear to have a diffuse hyperechoic pattern
compared to brain parenchyma but have an initial mild and
more homogeneous CE compared to GBMs, which is then
reinforced during the parenchymal phase.We found a diffuse
and persistent CE pattern in all cases, with scattered areas of
higher CE in one case, the brain tumor interface. Few small
hypoperfused areas were observed. Few intralesional vessels
were observed. The border of the tumor is less identifiable
than in GBMs. After high mechanical index sonication the
replenishing kinetics is around 10 seconds.
In the LGG group, CEUS patterns for ASTRO were
similar to ANAs. Nevertheless the vascular phases were
slower, with an arterial phase at 15 seconds and a CE peak at
around 20 seconds. The transit of the microbubbles appears
even more steady (15–20 sec) with a venous phase after 30
seconds. Arterial supply is not always clear, as well as the
venous drainage. ASTRO are mildly hyperechoic after UCA
compared to brain parenchyma, and the tumor parenchymal
phase is steady and uniform. Its CE pattern is dotted and
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Figure 1: Time frame of how different grades of glioma are visualized with CEUS. In the first column of each row low mechanical index US
and baseline CEUS (CA arrival – 𝑡
0
) are displayed; then different CEUS phases (time is displayed in the top right corner of each image) are
displayed only. The image clearly shows the differences in terms of timing, degree of enhancement, and CEUS patterns for different types of
glioma, with a continuous and dynamic modality.
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Figure 2: Schematic representation showing the differences in
terms of timing and degree of enhancement (light orange: mild
enhancement; dark orange: high enhancement) for different glioma
grades.
homogeneous, with only two caseswithmicrocystic areas. No
intralesional vesselswere noted.The replenishment kinetics is
similar to the initial CE phase with a timing of around 10–15
seconds.
In OLIGOs we found similar features as in ANAs. In two
cases the lesion was more well-defined, with faster arterial
and venous phase, similar to GBMs, with an intralesion cyst.
4. Discussion
In this paper we performed the first intraoperative human
cerebral gliomas characterization with the CEUS technique,
as already had been performed for different lesions in other
organs. The overall picture shows that in B-mode the main
differences between lesions at different grades of malignancy
are the degree of hyperechogenicity when compared to the
surrounding parenchyma, the presence of cystic/necrotic
areas, and a more or less defined brain/tumor interface.
These findings account for the fact that the role of B-mode
imaging ismainly limited in assisting tumor localization, pro-
viding only morphological information regarding the lesion,
with little or no information about vascularization [7, 8].
Conversely, once enhanced, the tumor is highlighted and
reveals other specific characteristics. These findings might
possibly be related to their grade (Figure 3). For exam-
ple, glioblastomas show rapid arterial and venous phase, a
clearly visible arterial supply and venous drainage, and a
very strong and intense contrast enhancement, with well-
defined tumor borders. Lower grades were characterized
by gradually less intense CE, less defined tumor borders,
slower arterial and venous phases, poorly identifiable feeders
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Figure 3: Comparison between standard gray-scale B-mode imaging and CEUS (resp., left and right picture in each panel) for different
glioma grades (panel a: LGG, panel b: ANA, and panel c: GBM).
and drainage, and a CE pattern progressively more homo-
geneous, accounting for the absence of necrotic/cystic areas
and a minor amount of neoangiogenesis. Surprisingly,
we observed a slighter but well-defined CE in low grades too,
where preoperative MRI did not show any enhancement. We
have been able to directly visualize each of the 69 lesions
both in B-mode and after contrast infusion, regardless of
its histology, thus making the comparison between the two
modalities always possible. We also observed different mor-
phologic and dynamic CEUS patterns, showing a very good
correlation with histopathology (Figures 1 and 2). This con-
firms once more the reliability of this technique in assisting
tumor resection. For the semiquantitative description of the
lesions which followed the EFSUMB guidelines [18], consider
parameters such as timing, degree of contrast enhancement
(low,mild, and high) compared to normal brain parenchyma,
diffuse or circumscribed appearance, homogeneous versus
heterogeneous lesions, presence of cystic/necrotic areas, the
pattern of CE, the timing of the different phases of CE, and
microbubbles transit time within the tumor. Also, the arterial
supply and the venous drainage were described when identi-
fied.
Of course CEUS cannot be considered as an alternative
to histological examination, which remains the gold standard
for diagnosis. Nevertheless, some of our cases considered
on preoperative MRI as being low-grade gliomas were later
histologically evaluated as anaplastic tumors. In these cases
we intraoperatively observed some areas of focal CEUS
enhancement. Therefore this technique can be helpful in
guiding the surgeon through the choice of the areas for
biopsy, thus possibly improving the accuracy of the final
histological diagnosis.
Another original aspect of our study is the unprece-
dented opportunity to conduct tumor resection under direct
visualization and to highlight tumor boundaries and tumor
remnants with CEUS during and after tumor resection.
Performing CEUS prior to glioma resection will help dif-
ferentiate tumor/edematous brain interface in HGG, and, as
mentioned above, it will be able to show anaplastic areas
within otherwise low-grade lesions (Figure 4).
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Figure 4: Intraoperative control of a right frontal GBM, using fusion imaging between intraoperative US (a1) and preoperative MRI (a2)
linked via a navigated US probe with a virtual navigation system: (a1) shows a hyperechoic superficial lesion, with ill-defined borders and
microcystic areas and in (a2) the correspondingMRI imaging is displayed. In panel (b) the B-mode imaging is enhancedwith a contrast agent,
showing a superficial nodular enhancement with a deeper ring enhancement delimitating a nonperfused necrotic central area. Medullary
draining veins are also visible, draining towards the ependymal zone. In panel (c) the postresection control with CEUS shows the absence of
the nodular ring enhancement, without contrast enhancement along the wall of the surgical cavity.
After tumor removal in 9 GBMs we performed CEUS in
order to highlight tumor remnants, thus possiblymaximizing
resection. In 3 cases we visualized CE areas which led to
further tissue removal, whereas in the other 6 cases CE was
not detected. Among the latter cases we also observed, in 2
cases, hyperechogenic areas in B-mode, suggestive for tumor
residual which did not show any clear enhancement after
contrast injection: in these cases the surgeon is facing one
of the following possible situations. Either the area identified
is a parenchymal contusion, which is hyperechoic due to the
presence of blood cloth and this can be better discerned by
visual inspection, or the hyperechoic area might represent
a devascularized tumoral area: in fact, one should always
keep in mind that microbubble contrast agents are confined
to the intravascular compartment, unlike those used for CT
or MRI enhancing, which mainly diffuse in the interstitial
space. Therefore the closure of a tumor feeding artery
leads to a noncontrasted area even when tumor is present.
For the same reason, tumorswith a greater degree of vascular-
ization (i.e., GBMs) will be more clearly distinguishable from
the surrounding healthy parenchyma, presenting with more
defined borders as compared to less vascularized ones.
The capacity of CEUS to almost invariably visualize,
in higher grades, feeding arteries and venous drainage is
helpful for the intraoperative management of the surgical
strategy, for example, by discerning whether a vessel is an
actual tumor feeder, being as such safely subject to closure by
cauterization, or is a vessel which is just passing through the
tumor, heading to a portion of healthy parenchyma.Of course
an early identification of a true feeder helps in controlling
any major bleeding and in keeping the operatory field clean,
while recognizing and preserving a vessel which is not strictly
related to the tumor can prevent unexpected complications.
In the literature few studies using bedside transcranial
US have been performed to evaluate the role of iCEUS in
depicting cerebral tumors [29–31]. Harrer et al. used bedside
transcranial CEUS prior to surgery and had been capable
of discriminating brain lesions from the brain parenchyma
and of partially describing them. Vicenzini et al. performed
time intensity/curves using dedicated software: indeed
time-intensity curves should be performed on a large sample
size in order to provide statistically relevant results [28].
However tumor visualization was somehow poor due to
transcranial US performed through a temporal window:
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despite being a well-established technique it suffers from
limitations to tumor visualization due to the presence of
the cranial vault in terms of both spatial resolution and
tumor location. Intraoperative iCEUS permitting direct
tumor visualization during surgery for brain tumor removal
has been described only a few times [25–27]. Kanno and
colleagues in 2005 evaluated that 40 brain tumors did not
perform a continuous imaging because they used a first
generation contrast agent. Engelhardt and colleagues in 2008
performed iCEUS during brain tumor removal, using a
second generation contrast agent with specific algorithm
on a very small and homogeneous cohort of patients (7
GBM patients). They also performed an offline analysis with
time-intensity curves. He and colleagues evaluated 29 brain
tumors using iCEUS but with some technical limitations:
they used a phased array probe, with low frequency and a
vast view-field, and the US imaging was performed in power
Doppler modality instead of using a contrast specific algo-
rithm, dramatically reducing both US spatial resolution and
definition.
Of course, further studies are needed in order to assess
CEUS role in tumor resection; the potentiality of this tech-
nique to maximize tumor resection has yet to be investi-
gated and demonstrated. Comparison with other imaging
modalities (such as MRI imaging T1 weighted GD) will be
necessary for defining further advantages or limitations of
this technique when compared with other imaging standards
in actual practice. Moreover, further studies aimed at quanti-
tative data analysis are mandatory for a rigorous validation
of the method: these results will further improve CEUS
characterization of cerebral gliomas and will also enhance
knowledge of tumor biology, possibly leading to prediction of
the responsiveness to therapy of a specific individual tumor,
or to orientation during the choice of the best therapeutic
option [32, 33].
In fact, one major limitation of this study is related to
the semiquantitative nature of the analysis that has been
performed on the data obtained by CEUS. Nondestructive
US scanning, with specific algorithm performed with low
acoustic power and sulfur hexafluoride, filled microbubble
contrast agents, opens up to quantitative data analysis with
dedicated software leading to real-time assessment and quan-
tification of tumor contrast enhancement with microbub-
bles, measurement of organ transit time after microbubble
injection, and analysis of tissue perfusion. Tissue perfusion
may be quantified also by further evaluating the replen-
ishment kinetics of the volume of microbubbles after their
destruction in the imaged slice (using high mechanical index
US), obtaining quantitative parameters related to local tissue
perfusion [15, 19]. However, we believe that the first step, as
already performed for other organs and in our previous study
[34], is the qualitative and semiquantitative analysis; time-
intensity curves providing quantitative data require very large
cohorts of patients in order to achieve a statistical relevance,
so we feel that a quantitative analysis would be of little value
in this study [28, 29, 32, 33].
Finally, another limitation related to the technique might
be that CEUS, as any method based on ultrasound imag-
ing, is dependent on the experience of the examiner [35].
Moreover, in the neurosurgical community, few surgeons
are accustomed to and specifically trained in the use of
ultrasounds, and this is especially true for CEUS, since its
use in neurosurgery is relatively new. Therefore, for a correct
image interpretation a period of specific training is required.
5. Conclusions
In this paper we establish for the first time a CEUS character-
ization of cerebral gliomas.
By defining the paradigm of CEUS enhancement in
gliomas, we add valuable biological information such as vas-
cularization, microcirculation, and tissue perfusion dynamic
and add these pieces of information to those obtained with
standardB-mode imaging andmight corroborate histological
diagnosis.
Performing CEUS during glioma removal can be helpful
for the surgeon to differentiate between tumor and ede-
matous brain in HGG, while it will show anaplastic areas
within otherwise considered low-grade lesions. After gross
tumor removal CEUS might also be used in the future
to highlight tumor remnants, thus maximizing resection
avoiding neurological sequelae due to damaged healthy
brain tissue. This may lead to reduction of hospitaliza-
tion time and ameliorating prognosis, improving free sur-
vival rates and ameliorating the quality of life in glioma
patients.
CEUS can be a fast, safe, dynamic, feasible and repeatable,
relatively economic, precise, and accurate tool that helps in
differentiating malignant and benign lesions and in maxi-
mizing tumor resection, thus improving free survival rates
in glioma patients; we believe that CEUS is definitely a
methodology to further understand and develop in glioma
surgery and the expected results will certainly integrate
scientific excellence possibly leading to better treatment for
cerebral tumors bearing patients.
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